Long-term Outcomes and Emerging Combinations With Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A GameOn! Challenge

CME: 0.5

October 17, 2022
/ Print / Reprints /
| Share More
/ Text Size+

Target Audience

The intended audience for this activity is oncologists and other health care professionals involved in the management of patients with non-small cell lung cancer.

Program Overview

Treatment of advanced non-small cell lung cancer (NSCLC) has rapidly evolved with the availability of immune checkpoint inhibitor (ICI) therapy. The integration of immunotherapy into treatment protocols offers the potential for durable treatment responses and improved survival for patients with tumors that lack targetable molecular alterations. As increased long-term data become available on the safety and efficacy of ICI therapy, evidence is emerging on novel immunotherapy combinations that may further improve patient outcomes in advanced NSCLC. In this CME activity, participants will play GameOn!, an interactive quiz of knowledge and confidence, in which they answer questions on long-term outcomes with immunotherapy, novel treatment combinations, and emerging agents. Through this gaming activity, faculty offer insight into current best practices and emerging approaches using ICIs for first-line therapy of advanced NSCLC and treatment of progressive disease.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Outline clinical evidence regarding long-term outcomes of available immune checkpoint inhibitors and combinations in patients with advanced NSCLC lacking targetable molecular aberrations.
  • Identify treatment options for patients with advanced NSCLC lacking oncogenic driver aberrations based on available long-term evidence, PD-L1 levels, safety considerations, and patient preferences.
  • Evaluate the latest data regarding emerging combinations for first-line therapy of advanced NSCLC lacking targetable driver alterations.
  • Discuss the potential roles for emerging combinations in the treatment of progressive disease based on mechanisms of action and available clinical data.

Post a comment to this article